Safety profile of olanzapine/samidorphan: focus on metabolic risks, opioid-related effects, and novel adverse events identified
Naunyn-Schmiedeberg's Archives of Pharmacology · 2026-03 · 399 (5) · 6849-6859
DOI: 10.1007/s00210-025-04818-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, online erschienen am 28.11.2025. Verfasst von Xiangyu Li und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Shaoxing Keqiao Women & Children's Hospital, Shaoxing, Zhejiang, China. Hauptthemen laut MEDLINE: Olanzapine, Antipsychotic Agents, Naltrexone, Metabolic Diseases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Themen: Patientensicherheit
Abstract (Originalsprache)
Olanzapine/samidorphan (O/S) represents an innovative therapeutic alternative for adult patients with schizophrenia and bipolar I disorder. However, most available safety data stems from clinical trials, limiting the ability to rapidly update emerging adverse events (AEs). O/S-related AEs, with a particular focus on metabolic diseases and novel signals (included opioid interference and psychiatric AEs), were systematically analyzed using the FDA Adverse Event Reporting System (FAERS) database in this study. Four disproportionality methods were utilized to assess the relationship between O/S and AEs from May 2021 (O/S first approved) to September 2024 using the FAERS database. Metabolic disease risk associated with O/S and olanzapine was compared using the reporting odds ratio method. A total of 2080 AE reports with O/S identified as the "primary suspect" were analyzed. Seventy-five preferred term signals and 23 system organ classifications were identified, predominantly within psychiatric disorders (19.37%). Nearly 20 novel potential AEs were identified. Although the overall risk of O/S-related metabolic diseases was lower than that of olanzapine (reporting odds ratio (ROR) [95% CI]: 3.55 [2.48-4.54] vs. 4.79 [4.51-5.08]), it still needs to be focused on. Notably, diabetic retinal edema and ketosis-prone diabetes mellitus presented the highest signal intensity for O/S and olanzapine, respectively. Psychiatric disorders, notably suicidal ideation, require vigilant monitoring in clinical settings. It is imperative to conduct traditional pharmacoepidemiological research to evaluate risk factors of O/S-related metabolic diseases in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Shaoxing Keqiao Women & Children's Hospital, Shaoxing, Zhejiang, China.
- Shaoxing Second Hospital, Shaoxing, Zhejiang, China.
- Department of Pharmacy, Shaoxing Central Hospital, Shaoxing, Zhejiang, China. 15157522780@163.com.
Zitieren
APA
Li, X., Yuan, L., & Li, J. (2026). Safety profile of olanzapine/samidorphan: focus on metabolic risks, opioid-related effects, and novel adverse events identified. Naunyn-Schmiedeberg's Archives of Pharmacology, 399(5), 6849-6859. https://doi.org/10.1007/s00210-025-04818-0
Vancouver
Li X, Yuan L, Li J. Safety profile of olanzapine/samidorphan: focus on metabolic risks, opioid-related effects, and novel adverse events identified. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026;399(5):6849-6859. doi:10.1007/s00210-025-04818-0
BibTeX
@article{Li2026,
author = {Li, Xiangyu and Yuan, Lingjing and Li, Jiandi},
title = {Safety profile of olanzapine/samidorphan: focus on metabolic risks, opioid-related effects, and novel adverse events identified},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2026},
volume = {399},
number = {5},
pages = {6849--6859},
doi = {10.1007/s00210-025-04818-0}
}
EUVIMED